Overview
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
Status:
Completed
Completed
Trial end date:
2009-12-01
2009-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc
Criteria
Inclusion Criteria:- stage IIIB or IV NSCLC
- eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab
Exclusion Criteria:
- mixed large and small cell histologies for lung cancer
- significant obesity, BMI > 30